Lori Ann Cox

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King, Emma Guttman‐Yassky, Elena Peeva et al. · Journal of the American Academy of Dermatology · 2021 · 184 citations · Full text

Backgroundalopecia Areata, Pharmacology, Clinical Trials +10

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi et al. · Journal of the American Academy of Dermatology · 2022 · 126 citations · Full text

Translational Medicine, Active Nonsegmental Vitiligo, Pharmacology +5

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology · 2021 · 91 citations · Full text

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

G Schmieder, Zoé Kececioglu Draelos, David M. Pariser et al. · British Journal of Dermatology · 2017 · 87 citations

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Michael F. Robinson, Nemanja Damjanov, Bojana Stamenković et al. · Arthritis & Rheumatology · 2020 · 84 citations · Full text